

Electronic Supplementary Material (ESI) for New Journal of Chemistry.

This journal is © The Royal Society of Chemistry and the Centre National de la Recherche Scientifique 2019

**Copper(II) complexes based on levofloxacin and 2N-donor ligands:
synthesis, crystal structures and *in vitro* biological evaluation**

Manish Kumar^a, Gyanendra Kumar^a, Kanhaiya M. Dadure^b, Dhanraj T. Masram^{a*}

^aDepartment of Chemistry, University of Delhi, Delhi-110007, India

^bJ.B. College of Science Wardha, Maharashtra 442001, India

Supplementary material file

*Corresponding author: *E-mail*; ghanraj_masram27@rediffmail.com; *Tel.*;
+91-11-27666646

Crystallographic data

Table S1. Crystallographic data collection and structural refinement parameters for complexes **1** and **2**.

	(1)	(2)
Formula	C ₂₈ H ₂₉ Cl ₃ CuFN ₆ O ₄	C ₄₂ H ₃₆ Cl ₃ CuFN ₅ O ₄
<i>M_w</i>	702.46	863.65
<i>T</i> (K)	298	293 (2)
Crystal system	monoclinic	triclinic
Space group	P 21/n	P -1
<i>a</i> , Å	15.1992 (16)	12.5234(11)
<i>b</i> , Å	13.4765 (11)	13.0688(14)
<i>c</i> , Å	15.5358 (17)	13.2794(12)
α (°)	90	101.577 (8)
β (°)	103.078 (11)	108.055 (8)
γ (°)	90	94.122 (8)
Volume Å ³	3099.7 (6)	2003.2 (3)
<i>Z</i>	4	2
<i>Z'</i>	1	1
<i>D</i> _{calc} /g cm ⁻³	1.505	1.432
μ /mm ⁻¹	1.013	0.799
Crystal size/mm ³	0.09×0.08×0.07	0.09×0.07×0.06
Colour	Blue	Light green
Wavelength/Å	0.71073	0.71073
Radiation type	MoK α	MoK α
$\Theta_{\min}$ /°	3.310	3.425
$\Theta_{\max}$ /°	26.369	25.681
Measured Refl	41879	25765
Independent Refl.	6335	7589
Reflections with <i>I</i> >2(<i>I</i>)	4140	4868
<i>R</i> _{int}	0.0773	0.0919
Parameters	431	534
Restraints	109	24
Largest Peak	0.483	1.399
Deepest Hole	-0.408	-0.895
GooF	1.049	1.069
w <i>R</i> ₂ (all data)	0.1828	0.3031
w <i>R</i> ₂	0.1625	0.2669
<i>R</i> ₁ (all data)	0.1073	0.1410
<i>R</i> ₁	0.0696	0.1014

Table S2. Hydrogen bonding interactions in the structures of the complexes **1** and **2**.

$D-H\cdots A$	$D(D\cdots H)$ (Å)	$d(H\cdots A)$ (Å)	$d(D\cdots A)$ (Å)	$\angle(DHA)$ (°)
[Cu(<i>lvx</i>)(bipyam)Cl] ⁺ , (1)				
C(27)–H(27B)⋯O(4)	0.971	2.346	2.841	110.91
C(3)–H(3A)⋯O(3)	0.930	2.313	3.114	144.09
N(3)–H(3)⋯Cl(0A)	0.931	2.356	3.231	156.23
C(28)–H(28B)⋯Cl(1)	0.959	3.196	3.443	96.67
[Cu(<i>lvx</i>)(BPhen)Cl] ⁺ , (2)				
C(32)–H(32B)⋯Cl(1)	0.970	2.006	3.397	132.52
C(2)–H(2)⋯O(3)	0.929	2.461	3.217	136.31
C(41)–H(41B)⋯O(4)	0.970	2.419	2.871	108.00
N(5)–H(5)⋯Cl(2)	0.980	2.004	2.995	163.09
C(7)–H(7)⋯Cl(3)	0.930	2.617	3.349	136.00

Table S3. The BSA and HSA binding parameters (*K_{sv}*, *k_q*, *K*, *n*) derived for Cu(II) complexes at two different temperature 30 and 35°C.

Complexes	T (°C)	$K_{sv} \times 10^5$ (M ⁻¹)	$kq \times 10^{13}$ (M ⁻¹ s ⁻¹)	$K \times 10^5$ (M ⁻¹)	<i>n</i>
BSA					
1	30	4.31±0.01	4.31±0.01	2.88±0.02	1.05±0.03
	35	3.36±0.01	3.36±0.01	2.42±0.01	0.69±0.04
2	30	10.58±0.02	10.58±0.02	6.43±0.03	1.21±0.02
	35	5.37±0.02	5.37±0.02	5.82±0.06	1.35±0.03
HSA					
1	30	7.89±0.01	7.89±0.01	1.2±0.04	0.82±0.05
	35	7.42±0.02	7.42±0.02	1.1±0.02	1.13±0.03
2	30	1.12±0.01	1.12±0.01	0.69±0.01	1.45±0.01
	35	1.09±0.01	1.09±0.01	0.41±0.02	1.56±0.02


Table S4. Antibacterial assay of the compounds (*lvx* and complexes **1** and **2**) against *Gram*(+) positive bacterial pathogens.

Test pathogens	Concentration (µg/disc)	Compounds			Standard drug	Control DMSO (10µL/disc)
		<i>lvx</i>	<i>Complex 1</i>	<i>Complex 2</i>	<i>Neomycin sulfate</i>	
<i>Staphylococcus aureus</i>	10	0.7	1.0	1.2	1.4	
	20	1.1	1.6	1.7	1.9	
	30	1.3	1.9	2.1	2.3	–
	40	1.7	2.6	2.9	3.2	
	50	2.5	3.2	3.3	3.5	
	60	3.0	3.4	3.6	3.9	
<i>Bacillus subtilis</i>	10	0.5	1.2	1.0	1.4	
	20	1.0	1.5	1.5	1.8	
	30	1.4	1.9	1.9	2.1	–
	40	1.8	2.4	2.3	2.5	
	50	2.0	3.0	2.8	3.2	
	60	2.5	3.3	3.1	3.5	
<i>Enterococcus faecalis</i>	10	0.9	1.3	1.2	1.5	
	20	1.2	1.6	1.5	1.8	
	30	1.4	2.0	1.8	2.2	–
	40	2.0	2.3	2.2	2.4	
	50	2.6	2.8	2.5	2.9	
	60	2.8	3.0	2.8	3.2	
<i>Streptococcus pneumonia</i>	10	1.2	1.5	1.7	1.8	
	20	1.5	2.1	2.2	2.3	
	30	1.8	2.6	2.8	3.0	–
	40	2.3	2.9	3.1	3.3	
	50	2.8	3.2	3.5	3.6	
	60	3.0	3.6	3.7	4.0	


Table S5. Antibacterial assay of the compounds (*lvx* and complexes **1** and **2**) against *Gram*(–) bacterial pathogens.

Test pathogens	Concentration (µg/disc)	Compounds			Standard drug	Control DMSO (10 µL/disc)
		<i>lvx</i>	<i>Complex 1</i>	<i>Complex 2</i>	Neomycin sulfate	
<i>Proteus mirabilis</i>	10	1.1	1.4	1.3	1.5	–
	20	1.4	2.0	1.5	2.1	
	30	1.6	2.1	1.8	2.3	
	40	2.0	2.3	2.5	2.7	
	50	2.1	2.3	2.5	2.9	
	60	2.6	2.8	3.0	3.2	
<i>Shigella flexneri</i>	10	0.8	1.1	1.3	1.4	–
	20	1.2	1.4	1.5	1.7	
	30	1.7	1.8	1.9	2.1	
	40	2.0	2.3	2.2	2.5	
	50	2.4	2.5	2.9	3.1	
	60	2.7	2.8	3.2	3.4	
<i>Escherichia coli</i>	10	1.3	1.6	1.7	1.9	–
	20	1.6	1.8	1.8	2.1	
	30	2.1	2.3	2.5	2.7	
	40	2.5	3.1	3.2	3.3	
	50	3.4	3.7	3.8	4.0	
	60	3.6	4.0	4.1	4.2	
<i>Citrobacter species</i>	10	1.4	1.6	1.6	1.9	–
	20	1.7	2.0	1.9	2.5	
	30	2.4	2.5	2.6	3.0	
	40	2.6	2.8	2.9	3.8	
	50	3.3	3.4	3.6	3.9	
	60	3.5	3.7	3.8	4.1	
<i>Salmonella typhi</i>	10	1.2	1.3	1.4	1.5	–
	20	1.6	1.8	1.9	2.2	
	30	2.0	2.2	2.4	2.6	
	40	2.6	2.9	2.8	3.0	
	50	3.2	3.4	3.5	3.6	
	60	3.4	3.7	3.6	3.9	


Antibacterial Activity




Metal salts ($\text{CuCl}_2 \cdot 2\text{H}_2\text{O}$)




DMSO as control (No effect)



Effect of *lvx* on *S. flexneri*



Complex **1** over *E. coli*



Complex **2** over *E. coli*

Scheme 2. The *in vitro* antibacterial screening of metal salts ($\text{CuCl}_2 \cdot 2\text{H}_2\text{O}$), *lvx* and copper (II) complexes against *Gram*(+) and *Gram*(-) microorganisms.




Fig. S1. Intermolecular hydrogen bonding interactions in complex **(1)** leading to the formation of cage-like structure.




Fig. S2. Intermolecular hydrogen bonding interactions in complex **(2)** leading to the formation of sheet-like structure.

1. Mass Spectrum analysis




Fig. S3. ESI-MS spectrum of complex **1**.




Fig. S4. ESI-MS spectrum of complex 2.

2. LC-MS analysis




Fig. S5. LC-MS chromatography of the complex 1.




Fig. S6. LC-MS chromatography of the complex **2**.

3. Stability and solubility




Fig. S7. The stability plots of complexes **(a)** $[\text{Cu}(\text{lvx})(\text{bipyam})\text{Cl}]^+$, **(1)** and **(b)** $[\text{Cu}(\text{lvx})\text{BPhenCl}]^+$, **(2)** in DMSO and different pH range (5-8).

4. DNA binding studies




Fig. S8. UV spectra of CT DNA solution (90 μM) in buffer solution (150 mM NaCl and 15mM trisodium citrate at pH 7.2) were recorded in the absence as well presence of the increasing concentrations of the complexes **(a)** $[\text{Cu}(\text{lvx})(\text{bipyam})\text{Cl}]^+$, **(1)** and **(b)** $[\text{Cu}(\text{lvx})(\text{BPhen})\text{Cl}]^+$, **(2)**. The arrows represents the changes occurs during the addition of the complexes.

5. Cyclic voltammetry




Fig. S9. Cyclic voltammogram of 0.5 mM 1:2 dms:buffer solution of **(a)** $[\text{Cu}(\text{lvx})(\text{bipyam})\text{Cl}]^+$, **(1)** and **(b)** $[\text{Cu}(\text{lvx})(\text{BPhen})\text{Cl}]^+$, **(2)** in the absence as well as in the presence of CT DNA. Scan rate = 100 mV s^{-1} . Supporting electrolyte = buffer solution.

6. Ethidium Bromide




Fig. S10. Stern-Volmer quenching plots of EB bound to CT DNA for lvx and complexes (1) or (2).

7. Proteins binding studies

a. Stern-Volmer quenching plots at 25 °C




Fig. S11. Stern-Volmer quenching plots of (a) BSA (b) HSA for lvx and complexes (1) or (2) at 25 °C.

b. Scatchard plots at 25 °C

(a) (b)




Fig. S12. Scatchard plots of (a) BSA (b) HSA for lx and complexes (1) and (2) at 25 °C.

c. Scatchard plots at two different temperatures at 30 and 35 °C




Fig. S13. Scatchard plots of BSA for (a) complex (1) and (b) complex (2) at two different temperature 30 and 35°C.




Fig. S14. Scatchard plots of HSA for (a) complex (1) and (b) complex (2) at two different temperature 30 and 35°C.

8. van't Hoff plots




Fig. S15. The van't Hoff plots for the binding of BSA to the (a) complex (1) and (b) complex (2) at 298, 303, and 308 K (25, 30 and 35 °C).




Fig. S16. The van't Hoff plots for the binding of HSA to the (a) complex (1) and (b) complex (2) at 298, 303, and 308 K (25, 30 and 35 °C).